Abivax Reports Positive Phase 3 Obefazimod Maintenance Data
PARIS, France, June 29, 2026 Abivax SA announced positive topline results from ABTECT Maintenance Part 2, the supplemental portion...
Endoscopic Remission
Advertisement
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Advertisement
